Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
Clinical trial NCT04930094 · COMPLETED
Trial details
- NCT number
- NCT04930094
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-06
- Primary completion
- 2025-04-11
- Enrollment
- 354
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.